Theravance Biopharma (TBPH): Look Ahead To 2017 - Leerink

November 9, 2016 7:07 AM EST
Get Alerts TBPH Hot Sheet
Price: $31.98 +1.04%

Rating Summary:
    5 Buy, 0 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade TBPH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Theravance Biopharma (NASDAQ: TBPH) after the company reported a 3Q EPS loss of $0.73 and provided an update about its clinical programs.

Theravance previously guided to lower Vibativ sales of $3.8-4.0mm in recent offering documents, and the reported sales of $3.9mm were below consensus. Management explained that seasonality can impact Vibativ versus other antibiotic medications because Vibativ is administered for hospital-acquired infections that can fluctuate with the rate of surgical admissions during the quarter. The analyst thinks the result is still disappointing given the recent expansion of the sales force from 6 to 50 reps, but the real-world TOUR patient registry data presented at ID (Infectious Diseases) Week in late October should help with awareness. Consequently, he is keeping his existing forecast intact pending further analysis and the performance in 4Q.

No change to the price target of $33.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $26.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Add Your Comment